Alice Yu, MD presented “Case Discussions II-Complications and Recurrences” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
How to cite: Yu, Alice.“Case Discussions II-Complications and Recurrences” November, 2023. Accessed Aug 2024. https://grandroundsinurology.com/case-discussions-ii-complications-and-recurrences/
Case Discussions II-Complications and Recurrences – Summary
Abhinav Sidana, MD, MPH; Arvin K. George, MD; Phillip Stricker, MBBS; Taimur T. Shah, MD; Alice Yu, MD; and Thomas Frye, DO
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Abhinav Sidana, MD, MPH, is the Director of Prostate Cancer Focal Therapy, Director of GU Clinical Trials Urology Section, and Associate Professor of Surgery at the University of Chicago Medicine and Biological Sciences in Chicago, IL. Dr. Sidana earned his MD in 2007 from the All India Institute of Medical Sciences in New Delhi. Following this, he pursued a post-doctoral Fellowship in Urology at Johns Hopkins University School of Medicine in Baltimore, Maryland, during which he focused on translational projects relating to cancer immunotherapy and was instrumental in translating the preclinical work for a clinical trial studying cryo-immunotherapy. Subsequently, he completed his urology residency at the University of Cincinnati Medical Center and a urologic oncology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. Sidana’s current clinical practice includes both surgical and non-operative management of prostate, kidney, ureteral, testicular, and bladder cancers. His research interests include functional prostate imaging, image-guided and focal treatments for prostate cancer, and clinical trials on novel treatments for urologic cancers.
Arvin George, MD, serves as Director of Prostate Cancer Programs and Associate Professor (PAR) of Urology at Johns Hopkins School of Medicine in Baltimore, Maryland. He is a urologic surgeon who specializes in the diagnosis and management of genitourinary cancers. After obtaining his medical degree from the Royal College of Surgeons in Ireland, he completed his urology residency at the Smith Institute for Urology at the Hofstra North Shore-LIJ School of Medicine. He remained there to complete his endourology fellowship in New York, gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. George’s research interests include minimally-invasive and image-guided treatments, functional prostate imaging, and focal therapy for prostate cancer. His research aims to identify appropriate use for imaging in diagnosis, risk stratification, and management of prostate cancer, including active surveillance and selection/treatment of patients with novel focal therapy modalities.
Doctor Thomas Frye currently serves as Associate Professor of Urology and Vice Chair of Clinical Affairs for the Department of Urology at the University of Rochester Medical Center. Dr. Frye, is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of prostate and kidney cancers), and advanced open pelvic and retroperitoneal cancer surgery. He has a special interest and expertise in the management of localized prostate cancer with focal therapy. Dr. Frye has the most comprehensive focal therapy program in upstate New York and offers High Intensity Focused Ultrasound (HIFU), cryotherapy, as well as other ablative technologies. He also participates in national clinical trials evaluating the efficacy of focal therapy for prostate cancer.
Dr. Frye was the valedictorian of his class where he graduated with a Doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine. He went on to complete his urology residency at Southern Illinois University School of Medicine. Dr. Frye was chosen for the prestigious fellowship training in Urologic Oncology within The National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland.
Dr. Frye’s research projects focus on optimizing the screening, diagnosis and treatment of men with prostate cancer. During his fellowship, he worked extensively in refining the use of prostate MRIs in men on active surveillance. Dr. Frye's clinical research interest also includes advanced imaging for prostate cancer as well as focal therapy of prostate cancer.
Dr. Frye is involved in multiple specialty societies including the American Urological Association (AUA), Society of Urologic Oncology (SUO), American Society of Clinical Oncology, and Focal Therapy Society.
